Ito K - Search Results

1

Phosphate dysregulation via the XPR1-KIDINS220 protein complex is a therapeutic vulnerability in ovarian cancer.

Bondeson DP, Paolella BR, Asfaw A, Rothberg MV, Skipper TA, Langan C, Mesa G, Gonzalez A, Surface LE, Ito K, Kazachkova M, Colgan WN, Warren A, Dempster JM, Krill-Burger JM, Ericsson M, Tang AA, Fung I, Chambers ES, Abdusamad M, Dumont N, Doench JG, Piccioni F, Root DE, Boehm J, Hahn WC, Mannstadt M, McFarland JM, Vazquez F, Golub TR. Bondeson DP, et al. Among authors: ito k. Nat Cancer. 2022 Jun;3(6):681-695. doi: 10.1038/s43018-022-00360-7. Epub 2022 Apr 18. Nat Cancer. 2022. PMID: 35437317 Free PMC article.

2

A synthetic lethality-based strategy to treat cancers harboring a genetic deficiency in the chromatin remodeling factor BRG1.

Oike T, Ogiwara H, Tominaga Y, Ito K, Ando O, Tsuta K, Mizukami T, Shimada Y, Isomura H, Komachi M, Furuta K, Watanabe S, Nakano T, Yokota J, Kohno T. Oike T, et al. Among authors: ito k. Cancer Res. 2013 Sep 1;73(17):5508-18. doi: 10.1158/0008-5472.CAN-12-4593. Epub 2013 Jul 19. Cancer Res. 2013. PMID: 23872584

3

Epithelial-to-Mesenchymal Transition is a Cause of Both Intrinsic and Acquired Resistance to KRAS G12C Inhibitor in KRAS G12C-Mutant Non-Small Cell Lung Cancer.

Adachi Y, Ito K, Hayashi Y, Kimura R, Tan TZ, Yamaguchi R, Ebi H. Adachi Y, et al. Among authors: ito k. Clin Cancer Res. 2020 Nov 15;26(22):5962-5973. doi: 10.1158/1078-0432.CCR-20-2077. Epub 2020 Sep 8. Clin Cancer Res. 2020. PMID: 32900796

4

Disease control and objective responsive rates in randomized phase II trials evaluating non-first-line chemotherapy for non-small cell lung cancer: a systematic review of 74 trials.

Matsumoto H, Horita N, Ito K, Ebina-Shibuya R, Hara Y, Kobayashi N, Kaneko T. Matsumoto H, et al. Among authors: ito k. Transl Lung Cancer Res. 2021 May;10(5):2278-2289. doi: 10.21037/tlcr-20-1120. Transl Lung Cancer Res. 2021. PMID: 34164275 Free PMC article. Review.

5

Clinical utility of liquid biopsy for EGFR driver, T790M mutation and EGFR amplification in plasma in patients with acquired resistance to afatinib.

Oya Y, Yoshida T, Asada K, Oguri T, Inui N, Morikawa S, Ito K, Kimura T, Kunii E, Matsui T, Kubo A, Kato T, Abe T, Tsuda T, Hida T. Oya Y, et al. Among authors: ito k. BMC Cancer. 2021 Jan 12;21(1):57. doi: 10.1186/s12885-020-07777-2. BMC Cancer. 2021. PMID: 33435905 Free PMC article.

6

Propensity score analysis of overall survival between first- and second-generation EGFR-TKIs using real-world data.

Ito K, Murotani K, Kubo A, Kunii E, Taniguchi H, Shindoh J, Asada K, Imaizumi K, Takahashi K, Karayama M, Okuno M, Inui N, Hataji O, Morikawa S, Hayai S, Suda T, Abe T, Tsuda T, Yamagichi T, Kimura T, Oya Y, Yoshida T, Hida T. Ito K, et al. Cancer Sci. 2020 Oct;111(10):3705-3713. doi: 10.1111/cas.14560. Epub 2020 Aug 5. Cancer Sci. 2020. PMID: 32639668 Free PMC article.

7

Real-world efficacy of atezolizumab in non-small cell lung cancer: A multicenter cohort study focused on performance status and retreatment after failure of anti-PD-1 antibody.

Furuya N, Nishino M, Wakuda K, Ikeda S, Sato T, Ushio R, Tanzawa S, Sata M, Ito K. Furuya N, et al. Among authors: ito k. Thorac Cancer. 2021 Mar;12(5):613-618. doi: 10.1111/1759-7714.13824. Epub 2021 Jan 15. Thorac Cancer. 2021. PMID: 33448648 Free PMC article.

8

Real-world data on NGS using the Oncomine DxTT for detecting genetic alterations in non-small-cell lung cancer: WJOG13019L.

Sakata S, Otsubo K, Yoshida H, Ito K, Nakamura A, Teraoka S, Matsumoto N, Shiraishi Y, Haratani K, Tamiya M, Ikeda S, Miura S, Tanizaki J, Omori S, Yoshioka H, Hata A, Yamamoto N, Nakagawa K. Sakata S, et al. Among authors: ito k. Cancer Sci. 2022 Jan;113(1):221-228. doi: 10.1111/cas.15176. Epub 2021 Nov 7. Cancer Sci. 2022. PMID: 34704312 Free PMC article.

9

Forthcoming Phase II Study of Durvalumab (MEDI4736) Plus Chemotherapy for Small Cell Lung Cancer with Brain Metastases.

Shiraishi Y, Shimose T, Tsuchiya-Kawano Y, Ishii H, Daga H, Ito K, Saruwatari K, Okamoto I. Shiraishi Y, et al. Among authors: ito k. Cancer Manag Res. 2022 Dec 14;14:3449-3453. doi: 10.2147/CMAR.S391220. eCollection 2022. Cancer Manag Res. 2022. PMID: 36540201 Free PMC article.

10

An exploration of the clinical progression models of osimertinib in the treatment of advanced EGFR-mutant non-small cell lung cancer.

Shi Y, Jiang Y, Pan B, Wang Z, Li H, Ma Y, Liu Y, He K, Wang Z, Lu J, Shi M, Shen B, Zhou G, Yin R, Rossi A, Ito K, Santarpia M, Um SW, Wang X, Chen C, Feng J. Shi Y, et al. Among authors: ito k. Transl Lung Cancer Res. 2022 May;11(5):817-831. doi: 10.21037/tlcr-22-315. Transl Lung Cancer Res. 2022. PMID: 35693279 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

11,900 results

Search Page